Abstract
Significant preclinical and early clinical data suggest radiotherapy may augment the effects of immune checkpoint inhibitors (ICI). Limited successful treatment options are available following progression on ICI. We hypothesized that fractionated, stereotactic ablative radiotherapy (SABR) would induce a response in combination with the PD-1 inhibitor avelumab in patients with non-small cell lung cancer (NSCLC) who previously progressed on ICI, either as monotherapy or combination therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
